Inhibrx Biosciences INBX 深 滬
等待開盤 09-08 09:30:00 美东时间
121.17
-1.090
-0.89%
華盛通- 最 高124.19
- 今 開121.04
- 成交量 19.65万股
- 最 低 120.48
- 昨 收 122.26
- 總市值 178.33万
- 52周最高 155.29
- 市盈率 靜 --
- 換手率 1335.22%
- 52周最低 26.19
- 委 比 -4.31%
- 總股本 1.47万
- 歷史最高 155.29
- 量 比 0.79
- 振 幅 3.03%
- 歷史最低 7.67
- 每 手 1
- 風險率 25.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candi...
09-05 04:02
美股周涨跌榜 | 绩优股周内集体飙升！爱芬奇劲升36%，Okta升23%，赛富时升逾22%
绩优股周内集体飙升！爱芬奇劲升36%，Okta升23%，赛富时升逾22%；RZLV升逾20%，与谷歌达成数据库技术合作>>
08-29 10:29
美股牛股 | Capricor飙近22%，获大行上调目标价至54美元；机器人股RR、稀土概念股Critical Metals双双升逾21%
Capricor隔夜飙升21.9%，获大行上调目标价至54美元；Richtech Robotics升21.6%，宣布1200万美元股票回购计划；稀土概念股Critical Metals劲升21.4%>>
08-26 19:31
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245
HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.
08-24 18:21
Inhibrx Biosciences Expands Credit Facility to $500 Million
Inhibrx Biosciences Inc ( ($INBX) ) just unveiled an announcement. On July 15, ...
07-17 17:17
Inhibrx BLA for ozekibart accepted by FDA
The US FDA has accepted for review Inhibrx Biosciences' (INBX) BLA for ozekibart to treat unresectable or metastatic conventional chondrosarcoma. The application has an action date of April 14, 2027. ...
06-15 22:34
Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma SAN DIEGO, June 15, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ...
06-15 21:19
科望医药 Elpiscience-B，递交IPO招股书，拟赴香港上市，中信证券独家保荐
2026年5月27日，来自江苏苏州的科望医药集团Elpiscience Biopharmaceuticals, Inc.(简称科望医药)在港交所递交...
06-07 21:27
